HealthcareServices

Sacroiliitis Treatment Industry Forecast to Hit $2.33 Billion by 2029 With a Strong 7.2% CAGR

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Future Market Size Estimation For The Sacroiliitis Treatment Market Covering 2025–2034?#_x000D_

The sacroiliitis treatment market has seen significant growth in its size over recent years. Its expansion is projected from $1.64 billion in 2024 to reach $1.77 billion by 2025, at a compound annual growth rate (CAGR) of 7.5%. This historical growth stemmed from several factors, including a rise in lower back pain cases, increased demand for early diagnosis, more sports-related pelvic injuries, the growing utilization of advanced imaging techniques, and a heightened focus on minimally invasive treatments._x000D_

_x000D_

The sacroiliitis treatment market is projected to experience robust expansion in the coming years. This market is anticipated to reach $2.33 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.2%. This expansion during the forecast period is fueled by several factors, including heightened investment in research and development (R&D) for innovative therapeutics, the growing acceptance of telemedicine for managing chronic pain, an increase in the prevalence of autoimmune diseases, the wider availability of targeted biologic treatments, and the increasing preference for personalized medicine strategies. Key trends anticipated during this period encompass progress in targeted drug delivery systems, the emergence of customized treatment methodologies, breakthroughs in regenerative medicine, enhancements in robotic-assisted surgical techniques, and the formulation of combination therapy regimens._x000D_

_x000D_

#Unlock Your Free Sample Report for Exclusive Market Data:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24688&type=smp_x000D_

_x000D_

#What Are The Drivers Pushing New Developments In The Sacroiliitis Treatment Market?#_x000D_

The rising occurrence of joint disorders is anticipated to propel the expansion of the sacroiliitis treatment market moving forward. Joint disorders are medical conditions that affect the joints, causing pain, inflammation, stiffness, and restricted movement due to factors such as injury, aging, autoimmune diseases, or infections. The frequency of joint disorders is on the rise primarily because older populations experience natural wear and tear on their joints, leading to a higher prevalence of conditions like osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment proves beneficial for joint disorders as it helps to decrease inflammation and pain in the sacroiliac joints, enhancing mobility and overall joint function, which can alleviate symptoms and prevent further joint damage. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government organization, osteoarthritis, a chronic condition involving the deterioration of joint cartilage, affected an estimated 2.1 million Australians (8.3%) in 2022, including 10% of women and 6.1% of men. Consequently, the increasing incidences of joint disorders are driving the growth of the sacroiliitis treatment market._x000D_

_x000D_

#What Are The Leading Segments Analyzed In The Sacroiliitis Treatment Market?#_x000D_

The sacroiliitis treatment market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation_x000D_

2) By Diagnosis: Imaging Tests, Physical Examination, Laboratory Tests, Other Diagnosis_x000D_

3) By Route Of Administration: Oral, Injectable, Topical_x000D_

4) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Medications: NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Agents, Analgesics_x000D_

2) By Joint Injections: Corticosteroid Injections, Platelet-Rich Plasma (PRP) Injections, Hyaluronic Acid Injections, Prolotherapy_x000D_

3) By Joint Fusion: Minimally Invasive SI Joint Fusion, Open SI Joint Fusion, Robotic-Assisted Fusion Techniques, Posterior Approach Fusion, Lateral Approach Fusion_x000D_

4) By Radiofrequency Denervation: Conventional Radiofrequency Ablation, Cooled Radiofrequency Ablation, Pulsed Radiofrequency Ablation_x000D_

5) By Electrical Stimulation: Transcutaneous Electrical Nerve Stimulation (TENS), Spinal Cord Stimulation (SCS), Peripheral Nerve Stimulation (PNS)_x000D_

_x000D_

#Which Competitive Trends Are Defining The Sacroiliitis Treatment Market Structure?#_x000D_

Leading companies in the sacroiliitis treatment market are primarily concentrating on securing regulatory approvals to expedite the launch of novel therapies, ensure access to the market, and strengthen their competitive position. Regulatory approvals signify the official authorization from government health agencies, confirming that a medical treatment is both safe and effective for public consumption. For instance, in December 2023, Spinal Simplicity, a medical equipment manufacturer based in the US, received FDA 510(k) clearance for its Liberty-SI Lateral Implant System. This system is a minimally invasive, transfixing device specifically developed for sacroiliac joint fusion in individuals experiencing conditions such as sacroiliac disruptions and degenerative sacroiliitis. The system employs a lateral approach, where one or two titanium implants are inserted through the ilium and across the SI joint into the sacrum to achieve stabilization and fusion. These implants feature a central threaded body along with deployable wings and compressive elements, are available in multiple sizes, and are coated with hydroxyapatite to facilitate enhanced integration. The procedure is intended to offer a safer and less invasive option, potentially leading to reduced anesthesia time and improved outcomes for patients._x000D_

_x000D_

#Which Leading Companies Dominate The Sacroiliitis Treatment Market Share?#_x000D_

Major companies operating in the sacroiliitis treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Biogen Inc., Sandoz Group AG, UCB S.A., Hikma Pharmaceuticals PLC, Samsung Bioepis Co. Ltd., Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co. Ltd., Torrent Pharmaceuticals Limited, Globus Medical, Fortis Healthcare, Orthofix Medical Inc., Coherus BioSciences Inc., SI-BONE Inc. _x000D_

_x000D_

#Download The Full Report For Exclusive Market Findings:#_x000D_

https://www.thebusinessresearchcompany.com/report/sacroiliitis-treatment-global-market-report_x000D_

_x000D_

#How Do Regional Market Performances Compare Within The Sacroiliitis Treatment Industry?#_x000D_

North America was the largest region in the sacroiliitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sacroiliitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Version Of The Sacroiliitis Treatment Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=24688&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Sacroiliitis Treatment Market 2025, By The Business Research Company#_x000D_

_x000D_

Saccharin Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/saccharin-global-market-report_x000D_

_x000D_

Diverticulitis Disease Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report_x000D_

_x000D_